In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …

Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …

Background Impaired immune response in multiple myeloma renders the patients
vulnerable to infections, such as COVID-19, and may cause worse response to vaccines …

Simple Summary The current study provides data on the efficacy of COVID-19 prime-boost
vaccines in 200 patients with hematologic and predominantly lymphoid malignancies as …

Patients affected by multiple myeloma (MM) have an increased risk of severe acute
respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection and subsequent …

In the ongoing COVID-19 pandemic, patients with hematologic and oncological diseases
represent a heterogeneous population at risk of severe course of infection (Kuderer et al …

We investigated antibody and coronavirus disease 2019 (COVID‐19)‐specific T‐cell
mediated responses via ultra‐deep immunosequencing of the T‐cell receptor (TCR) …

Background Until now, most of the research addressing long-term humoral responses in
coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe …

Results Of the 31 patients enrolled in the M-PLACE study, 19 (61.3%) were vaccinated
against SARS-CoV-2. Among these patients, the median age was 63 years, 73.7% received …

The lives of people all over the world have been affected by the coronavirus disease 2019
(COVID-19) pandemic since 2019. The virus originated in Wuhan City, China, and many …